Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Information source: Medical University of South Carolina
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Social Anxiety Disorder; Social Phobia; Alcohol Use Disorder; Alcohol Abuse; Alcohol Dependence
Intervention: Paroxetine (Drug); Placebo (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Medical University of South Carolina Official(s) and/or principal investigator(s): Carrie L. Randall, PhD, Principal Investigator, Affiliation: Medical University of South Carolina
Summary
The purpose of the study is to determine whether an SSRI, paroxetine, improves social
anxiety symptoms and alcohol use in individuals who drink to cope with social anxiety
disorder.
Clinical Details
Official title: Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Social anxiety severityAlcohol use, quantity and frequency Drinking to cope, quantity and frequency
Secondary outcome: Quality of lifeDepressive symptoms
Detailed description:
Social anxiety disorder (also known as social phobia) is an Axis I anxiety disorder
characterized by intense fear and avoidance of social or performance situations in which one
might be scrutinized. Its onset is typically in the early teen years. It is the third most
common mental disorder in the United States, exceeded in prevalence only by depression and
alcoholism. Approximately 20% of the individuals with social anxiety disorder have alcohol
problems. Anecdotal and empirical evidence suggests that alcohol is used by some socially
anxious individuals to self-medicate anxiety symptoms, a practice that could lead to alcohol
abuse and/or dependence. The proposed project further explores the self-medication
hypothesis through the use of a double-blind, randomized, placebo-controlled clinical trial.
Paroxetine (a selective serotonin reuptake inhibitor) is the drug to be used in the study.
Individuals who drink alcohol to cope with social anxiety symptoms and who meet DSM-IV
criteria for the dual-diagnoses of social anxiety disorder and alcohol use disorders will be
enrolled in the trial. All individuals will be seeking treatment for social anxiety
disorder. The treatment phase will last 16 weeks. Dosing will start at 20 mg/day
(paroxetine or placebo) and will increase gradually to a maximum dose of 60 mg/day. Each
week during treatment and at the end of the trial, assessments will be made with standard
instruments to determine the effect of paroxetine (versus placebo) on social anxiety
severity, alcohol use, and more specifically, the intentional use of alcohol to cope with
social anxiety symptoms. Additionally, 6 month and 12 month follow-up interviews will be
conducted. The overarching hypothesis is that because paroxetine will improve social anxiety
severity, alcohol use and/or alcohol use for coping will also be reduced in the
paroxetine-treated group.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets DSM-IV criteria for current social anxiety disorder
- Reports social anxiety in most situations (generalized type).
- Treatment seeking for relief of social anxiety.
- Meets DSM-IV criteria for current alcohol use disorder
- Reads at the 6th grade level or above
- Endorses using alcohol to cope with social anxiety either "very often" or "always."
- Reports no prior medical alcohol detoxification
- Willingness to be randomized to the placebo group
- Willingness to attend 16 weekly medication management visits and one alcohol-related
therapy session
- Liebowitz Social Anxiety Scale Total score (modified version) of at least 60
- Endorses drinking at least 15 standard drinks in a typical 30 day period or reports
drinking heavily (defined as greater-than-or-equal-to 4 standard drinks on one
occasion for women; greater-than-or-equal-to 5 standard drinks on one occasion for
men, respectively) on at least 2 days in a typical 30 day period.
Exclusion Criteria:
- Abuse or dependence on drugs other than nicotine or marijuana in last 90 days
- Current or past diagnosis of bipolar disorder or schizophrenia
- Significant suicide risk as assessed by the SCID
- Current use of psychotropic medications
- Treatment seeking for alcohol problems
- Any unstable medical condition that might interfere with safe participation in the
trial
- Elevated liver enzymes (3 x greater than normal levels)
- History of adverse reaction to paroxetine
- History of failure to respond to adequate trial or dose of paroxetine for social
phobia (60 mg/day for at least 6 weeks)
- History of heart problems or abnormal ECG recording
- Pregnancy, nursing, or refusal to use effective birth control if sexually active and
premenopausal
- History of one or more alcohol detoxifications
Locations and Contacts
Medical University of South Carolina, Institute of Psychiatry, Charleston, South Carolina 29425, United States
Additional Information
Starting date: March 2002
Last updated: November 17, 2009
|